{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-073296","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2023-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.447417+00:00","generated_at":"2026-06-11T00:42:03.652842+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"MoonLake raises CEO, CSO, CFO salaries and bonuses citing MIRA trial success","bullets":["New annual base salaries July 1, 2023: CEO Jorge Santos da Silva CHF 600k (was CHF 450k), CSO Kristian Reich CHF 600k (was CHF 450k), CFO Matthias Bodenstedt CHF 475k (was CHF 325k).","Target bonuses raised to 55% of salary for CEO and CSO, 50% for CFO (previously 50%, 50%, 40% respectively).","Board cites positive Phase 2 MIRA trial results and peer benchmarking as rationale for adjustments."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-073296","json":"https://secwatch.observer/filing/0001213900-23-073296.json","markdown":"https://secwatch.observer/filing/0001213900-23-073296.md","text":"https://secwatch.observer/filing/0001213900-23-073296.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000121390023073296/0001213900-23-073296-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000121390023073296/ea184508-8k_moonlake.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:42:03.652842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}